MoFo Perspectives Podcast

MoFo Perspectives Podcast

By Morrison & Foerster LLP (MoFo)Business
Download on the App Store

MoFo Perspectives Podcast episodes

  • When Your Life Sciences Are on the Line Podcast Ep. 14: IP Disputes
    Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm’s Investigations + White Collar Defense Group, hosted the fourteenth episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector.
    32 min
  • When Your Life Sciences Are on the Line: Securities Litigation
    Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm’s Investigations + White Collar Defense Group, hosted the thirteenth episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector.
    16 min
  • Above Board: What Boards Need to Know About Prediction Markets
    In this episode of the Above Board podcast, hosts Scott Lesmes and Haima Marlier are joined by Morrison Foerster partners Trevor Levine and Ryan Adams to examine the rapid rise of prediction markets and the governance, compliance, and enforcement questions they raise for public companies. Trevor explains how prediction markets operate, why they fall under CFTC jurisdiction, and the regulatory safeguards built into these markets. Ryan then explores the insider trading and anti-fraud risks prediction markets create for public companies, particularly where employees may trade on confidential or non-public information tied to corporate events. The discussion closes with practical guidance for boards and legal teams, including why companies should proactively update insider trading policies, codes of conduct, and employee training to expressly address prediction market activity.
    21 min
  • When Your Life Sciences Are on the Line: AI and the FDA
    Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm’s Investigations + White Collar Defense Group, hosted the twelfth episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector.
    In this episode, Kate and Nate speak with Brigid Bondoc, partner and leader of Morrison Foerster’s U.S. Food and Drug Administration (FDA) & Healthcare Regulatory and Compliance Group. Together, they discuss the evolving role of artificial intelligence (AI) within the FDA and its implications for the life sciences industry. They address how the FDA is beginning to integrate AI tools like “Elsa” to improve efficiency in inspections, data analysis, and safety monitoring. Brigid also explores key regulatory and compliance challenges surrounding AI-driven clinical decision support software, emphasizing the importance of explainability and human oversight. The conversation closes with an examination of the FDA’s new approach to releasing complete response letters, and how this increased transparency may reshape industry strategies for engagement with the agency.
    26 min
  • DCP+ Episode 3: AI and the Evolution of National Security Policy
    In this episode of our Data, Cyber + Privacy PLUS podcast, hosts Kaylee Cox Bankston and Boris Segalis sit down with Carrie Cordero, General Counsel and Robert M. Gates Senior Fellow at the Center for a New American Security, for a thought-provoking conversation about the emerging AI regulatory landscape, the bipartisan push to strengthen cybersecurity, and the growing influence of private-sector innovators in shaping national security policy.
    32 min

About MoFo Perspectives Podcast

From the publisher's feed

We are Morrison & Foerster. We are MoFo. We are synonymous with a commitment to client service and advisors to market-changing deals and impact litigation.